Select Publications

Grothey A et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. Proc ASCO 2008;Abstract 4010.

Hochster HS et al. Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOX + bevacizumab (BEV) in the CONcePT trial. Gastrointestinal Cancers Symposium 2008;Abstract 280.

Kesmodel SB et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer
liver metastases. J Clin Oncol 2008;26(32):5254-60. Abstract

Saltz LB et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin
Oncol 2008;26(12):2013-9. Abstract

Tournigand C et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer — A GERCOR study. J Clin Oncol 2006;24(3):394-400. Abstract

Van Cutsem E et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. Proc ASCO 2008;Abstract 2.